The
FDA
approved
PI
3K inhibitor
GDC
‐0941 enhances
in vitro
the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma
Journal of Cellular and Molecular Medicine(2018)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要